Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/ TP 53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

Blood (2016) 128 (22): 2038.

https://doi.org/10.1182/blood.V128.22.2038.2038

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation Versus B-Cell-Receptor Inhibitors in 17p Deletion and/or Refractory Chronic Lymphocytic Leukemia: A Retrospective Comparative Analysis of 'Real Life' Approaches to High Risk Patients, on Behalf of Rete Ematologica Lombarda (REL) and Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Lucia Farina, MD PhD, Francesca Patriarca, Maddalena Mazzucchelli, Chiara Salvetti, MD, Giulia Quaresmini, Marta Medeot, MD, Daniele Vincenti, Gianluigi Reda, MD, Andrea Ferrario, MD, Francesco Zallio, MD, Anna Dodero, Benedetto Bruno, MD PhD, Paolo Corradini, Marco Montillo, MD

Blood (2016) 128 (22): 4695.

https://doi.org/10.1182/blood.V128.22.4695.4695

Published: 2016

Journal Articles

Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS)

Anna Dodero, Francesca Patriarca, Giuseppe Milone, MD, Barbara Sarina, MD, Rosalba Miceli, Anna Paola Iori, Francesco Barretta, Elisabetta Terruzzi, MD, Alberto Mussetti, MD, Massimo Pini, MD, Alberto Bosi, Alida Dominietto, MD, Nicola Cascavilla, MD, Francesco Onida, MD, Franco Narni, Lucia Farina, MD PhD, Alessandro Rambaldi, MD, Paolo Corradini

Blood (2016) 128 (22): 3473.

https://doi.org/10.1182/blood.V128.22.3473.3473

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes

Francesco Spina, MD, Serena Camilla Dalto, MD, Simonetta Viviani, MD, Chiara De Philippis, MD, Anna Dodero, MD, Lucia Farina, MD PhD, Vittorio Montefusco, Paolo Corradini, MD

Blood (2015) 126 (23): 2016.

https://doi.org/10.1182/blood.V126.23.2016.2016

Published: 2015

Journal Articles

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Blood (2015) 126 (23): 3937.

https://doi.org/10.1182/blood.V126.23.3937.3937

Published: 2015

Journal Articles

High Dose Chemotherapy with Autograft in First Relapse May Overcome the Poor Prognosis of Diffuse Large B-Cell Lymphoma Patients with MYC/BCL2 Co-Expression

Francesco Maura, MD, Anna Dodero, Alessio Pellegrinelli, MD, Martina Pennisi, Liliana Franca Devizzi, Anna Guidetti, MD, Cristiana Carniti, PhD, Lucia Farina, MD PhD, Antonello Cabras, MD, Paolo Corradini

Blood (2015) 126 (23): 1976.

https://doi.org/10.1182/blood.V126.23.1976.1976

Published: 2015

Journal Articles

A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients

Vittorio Montefusco, Francesco Spina, MD PhD, Elena Zamagni, MD, Benedetto Bruno, MD, Francesca Gay, Francesca Patriarca, MD, Giorgia Saporiti, MD, Monica Galli, MD, Claudia Crippa, MD, Lucia Farina, MD, PhD, Anna Maria Cafro, Angelo Michele Carella, MD, Paolo Corradini, MD

Blood (2012) 120 (21): 1960.

https://doi.org/10.1182/blood.V120.21.1960.1960

Published: 2012

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

The Therapeutic Effect of Lenalidomide Is Enhanced After Allogeneic Stem Cell Transplantation: Results of a Case-Control Study

Vittorio Montefusco, MD, Francesco Spina, MD, Elena Zamagni, MD, Giorgia Saporiti, MD, Francesca Patriarca, MD, Monica Galli, MD, Claudia Crippa, MD, Lucia Farina, MD, PhD, Anna Maria Cafro, Paolo Corradini, MD

Blood (2011) 118 (21): 1996.

https://doi.org/10.1182/blood.V118.21.1996.1996

Published: 2011

Journal Articles

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Anna Guidetti, MD, Silvia Locatelli, PhD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Domenico Russo, Pietro Bulian, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Andrea Anichini, PhD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 3705.

https://doi.org/10.1182/blood.V118.21.3705.3705

Published: 2011

Journal Articles

High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study

Vittorio Montefusco, MD, Francesco Spina, MD, Francesca Patriarca, MD, Massimo Offidani, MD, Benedetto Bruno, Lucia Farina, MD, PhD, Alessandra Sperotto, MD, Mara Morelli, MD, Anna Dodero, MD, Luisa Giaccone, Renato Fanin, Pinuccia Valagussa, Paolo Corradini, MD

Blood (2011) 118 (21): 828.

https://doi.org/10.1182/blood.V118.21.828.828

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and Treatment History.

Francesco Spina, MD, Emilio Paolo Alessandrino, MD, Lucia Farina, MD, PhD, Raffaella Milani, MD, Francesca Bonifazi, MD, Massimo Bernardi, MD, Roberto Lucksh, MD, Franca Fagioli, MD, Paolo Corradini, MD

Blood (2010) 116 (21): 4577.

https://doi.org/10.1182/blood.V116.21.4577.4577

Published: 2010

Journal Articles

Donor Lymphocyte Infusions and Rituximab Are An Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced Intensity Allogeneic Stem Cell Transplantation.

Francesco Spina, MD, Francesca Patriarca, MD, Lucia Farina, MD, PhD, Vittorio Montefusco, MD, Anna Dodero, MD, Cristiana Carniti, PhD, Renato Fanin, MD, Paolo Corradini, MD

Blood (2009) 114 (22): 3310.

https://doi.org/10.1182/blood.V114.22.3310.3310

Published: 2009

NARROW

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/ TP 53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS)

Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

High Dose Chemotherapy with Autograft in First Relapse May Overcome the Poor Prognosis of Diffuse Large B-Cell Lymphoma Patients with MYC/BCL2 Co-Expression

A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

The Therapeutic Effect of Lenalidomide Is Enhanced After Allogeneic Stem Cell Transplantation: Results of a Case-Control Study

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study

Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and Treatment History.

Donor Lymphocyte Infusions and Rituximab Are An Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced Intensity Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only